Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis

Castéra, L.; Hézode, C.; Roudot-Thoraval, F.; Lonjon, I.; Zafrani, E-S.; Pawlotsky, J-M.; Dhumeaux, D.
March 2004
Gut;Mar2004, Vol. 53 Issue 3, p420
Academic Journal
Background and aim: Recent studies suggest that liver steatosis in chronic hepatitis C may be the expression of a direct cytopathic effect of hepatitis C virus (HCV), particularly in patients infected with genotype 3. To investigate this hypothesis, we studied the relationship between steatosis evolution and HCV clearance after antivirol treatment in patients with chronic hepatitis C and paired liver biopsies. Methods: A total of 151 patients (37 with HCV genotype 3; 114 with HCV non-3 genotypes) were selected according to the following criteria: presence of steatosis at initial biopsy; no antiviral treatment prior to the first biopsy; antiviral treatment received between the two biopsies; body mass index (BMI) <28 kg/m²; absence of excessive alcohol intake; no serum hepatitis B surface antigen or human immunodeficiency virus antibodies; and absence of diabetes mellitus. Evolution of steatosis was examined by comparing steatosis grades between the two biopsies. Results: Twenty five patients (16.5%) were sustained virological responders (SVR) to antiviral treatment. Steatosis evolution after antiviral treatment was as follows: improvement in 36% of cases; stability in 51%; and worsening in 13%. Steatosis improvement was significantly more frequent in SVR than in non- responders (NR) (64% v 31%; p<.0.004). This significant difference occurred in patients infected with genotype 3 (91% v 19%; p<0.0001) but not in those infected with non-3 genotypes (43% v 34%; NS). Among the 25 SVR, improvement in steatosis was significantly more frequent in patients infected with genotype 3 than in those infected with non-3 genotypes (91% v 43%; p<0.04) whereas in NR, improvement in steatosis did not differ between those infected with genotype 3 and non-3 genotypes (1 9% v 34%; NS). In multivariate analysis, four factors were independently associated with steatosis improvement: sustained virological response to antiviral therapy (odds ratio (OR) 6.06 (95% confidence interval (CI) 1.61-22.9); p=0.01), severe steatosis (OR 5.50 (95% CI 1.54-19.6); p=0.01), HCV genotype 3 (OR 2.90(95% CI 0.85-10.0); p= 0.07), and BMI >25 kg/m² (OR 0.24 (95% CI 0.08-0.73); p=0.02). Conclusions: Our results showed significant improvement in steatosis in patients infected with HCV genotype 3, who achieved sustained viral clearance. This provides further evidence for direct involvement of HCV genotype 3 in the pathogenesis of hepatic steatosis.


Related Articles

  • Viral Sequence Variation in Chronic Carriers of Hepatitis C Virus Has a Low Impact on Liver Steatosis. Depla, Marion; D'Alteroche, Louis; Le Gouge, Amélie; Moreau, Alain; Hourioux, Christophe; Meunier, Jean-Christophe; Gaillard, Julien; De Muret, Anne; Bacq, Yannick; Kazemi, Farhad; Avargues, Aurélie; Roch, Emmanuelle; Piver, Eric; Gaudy-Graffin, Catherine; Giraudeau, Brunoq; Roingeard, Philippe // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Most clinical studies suggest that the prevalence and severity of liver steatosis are higher in patients infected with hepatitis C virus (HCV) genotype 3 than in patients infected with other genotypes. This may reflect the diversity and specific intrinsic properties of genotype 3 virus proteins....

  • Frequency distribution of HCV genotypes among chronic hepatitis C patients of Khyber Pakhtunkhwa. Ali, Sajid; Ali, Ijaz; Azam, Sadiq; Ahmad, Bashir // Virology Journal;2011, Vol. 8 Issue 1, p193 

    Background: Hepatitis C Virus (HCV) genotypes frequency is important for the predication of response to therapy and duration of treatment. Despite variable response rates experienced in the case of Interferon (IFN) -based therapies, there was scarcity of data on HCV genotypes frequency in Khyber...

  • Selection of hepatitis C virus resistant to ribavirin.  // Virology Journal;2011, Vol. 8 Issue 1, p402 

    The article focuses on a study conducted to identify the effects of ribavirin on hepatitis C virus (HCV) replication, which found that virus replication was dramatically reduced by concentrations of 250 uM of ribavirin which was sustained over six passages. The study found that the selection of...

  • Inhibition of full length Hepatitis C Virus particles of 1a genotype through small interference RNA. Ansar, Muhammad; Ashfaq, Usman Ali; shahid, Imran; Sarwar, Muhammad Tahir; Javed, Tariq; Rehman, Sidra; Hassan, Sajida; Riazuddin, Sheikh // Virology Journal;2011, Vol. 8 Issue 1, p203 

    Background: Hepatitis C virus (HCV), a member of the Flaviviridae family of viruses, is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Currently, the only treatment available consists of a combination of Pegylated interferon alpha (INF-α) and ribavirin, but...

  • Manage psychiatric and/or substance use comorbidities in patients with hepatitis C virus infection to improve antiviral outcomes.  // Drugs & Therapy Perspectives;Oct2006, Vol. 22 Issue 10, p14 

    Treatment of hepatitis C virus (HCV) infection is often complicated by comorbidity with psychiatric and/or substance use disorders. Before initiation of interferon therapy, patients with HCV should be screened for psychiatric and substance use disorders. Most of the recent evidence suggests...

  • Assessment of the PHQ-9 as a Screening Tool for Depression in Patients with Chronic Hepatitis C. Nader Dbouk; Miguel Arguedas; Aasim Sheikh // Digestive Diseases & Sciences;Apr2008, Vol. 53 Issue 4, p1100 

    Abstract   Background and Objectives We examined the test characteristics of the PHQ-9, a new screening tool that has been validated in the general population but not amongst patients with hepatitis C virus (HCV). Methods The PHQ-9, CES-D and BDI-II questionnaires were...

  • The prevalence of GB virus C/hepatitis G virus RNA among healthy and HCV-infected Catalan children. Claret, Gemma; Noguera, Antoni; González-Cuevas, Araceli; García-García, Juan; Fortuny, Clñudia; Muñoz-Almagro, Carmen; González-Cuevas, Araceli; García-García, Juan José; Fortuny, Clàudia; Muñoz-Almagro, Carmen // European Journal of Pediatrics;Sep2008, Vol. 167 Issue 9, p991 

    GB virus C (GBV-C) is a blood-borne flavivirus. The prevalence of GBV-C viremia among healthy adults is 0.5% to 4% and, to date, no disease has been definitely associated with GBV-C infection. We conducted a cross-sectional study to evaluate GBV-C viremia prevalence in a group of 327 healthy...

  • Cost-Effectiveness of Combination Peginterferonα-2a and Ribavirin Compared With Interferonα-2b and Ribavirin in Patients With Chronic Hepatitis C. Sullivan, S. D.; Jensen, D. M.; Bernstein, D. E.; Hassanein, T. I.; Foster, G. R.; Lee, S. S.; Cheinquer, H.; Craxi, A.; Cooksley, Graham; Klaskala, W.; Pettit, K.; Patel, K. K.; Green, J. // American Journal of Gastroenterology;Aug2004, Vol. 99 Issue 8, p1490 

    BACKGROUND: Sustained virological response (SVR) is the primary objective in the treatment of chronic hepatitis C (CHC). Results from a recent clinical trial of patients with previously untreated CHC demonstrate that the combination of peginterferonα-2a and ribavirin produces a greater SVR...

  • Fibrosis progression in chronic hepatitis C virus infection. McCaughan, G. W.; George, J. // Gut;Mar2004, Vol. 53 Issue 3, p318 

    Chronic hepatitis C virus infection is typically characterised by slowly progressive hepatic fibrosis. However, it is recognised that some patients do not progress while others rapidly develop significant fibrosis. Here, we review studies that have assessed factors that could influence this rate...


Read the Article


Sign out of this library

Other Topics